The current study explored whether intra-articular (IA) injection of autologous adipose mesenchymal stem cells (ASCs) combined with hyaluronic acid (HA) achieved better therapeutic efficacy than autologous stromal vascular fraction (SVF) combined with HA to prevent osteoarthritis (OA) progression and determined how long autologous ASCs combined with HA must remain in the joint to observe efficacy. OA models were established by performing anterior cruciate ligament transection (ACLT) and medial meniscectomy (MM). Autologous SVF (1Â10 7 mononuclear cells), autologous low-dose ASCs ( 1Â10 7 ), and autologous high-dose ASCs ( 5Â10 7 ) combined with HA, and HA alone, or saline alone were injected into the OA model animals at 12 and 15 weeks after surgery, respectively. Compared with SVFþHA treatment, low-dose ASCþHA treatment yielded better magnetic resonance imaging (MRI) scores and macroscopic results, while the cartilage thickness of the tibial plateau did not differ between low, high ASCþHA and SVFþHA treatments detected by micro-computed tomography (mCT). Immunohistochemistry revealed that high-dose ASCþHA treatment rescued hypertrophic chondrocytes expressing collagen X in the deep area of articular cartilage. Western blotting analysis indicated the high-and low-dose ASCþHA groups expressed more collagen X than did the SVFþHA group. Enzyme-linked immunosorbent assay showed treatment with both ASCþHA and SVFþHA resulted in differing anti-inflammatory and trophic effects. Moreover, superparamagnetic iron oxide particle (SPIO)-labeled autologous ASC signals were detected by MRI at 2 and 18 weeks post-injection and were found in the lateral meniscus at 2 weeks and in the marrow cavity of the femoral condyle at 18 weeks post-injection. Thus, IA injection of autologous ASCþHA may demonstrate better efficacy than autologous SVFþHA in blocking OA progression and promoting cartilage regeneration, and autologous ASCs (5Â10 7 cells) combined with HA potentially survive for at least 18 weeks after IA injection.
Introduction
Osteoarthritis (OA) is the most prevalent and debilitating musculoskeletal disorder and is characterized by micro-and macro-injury-induced cell stress and extracellular matrix degradation that activates maladaptive repair responses, including pro-inflammatory innate immunity pathways 1 . As an organ disease, the pathological changes induced by OA include cartilage degradation, subchondral bone sclerosis, ligament retrogression, synovium hyperplasia, and joint capsule hypertrophy 2 . However, current existing therapies for OA primarily consist of symptom-modifying drugs in combination with nonsteroidal anti-inflammatory drugs (NSAIDs) 3 and/or joint lubricants such as hyaluronic acid (HA) 4 to reduce the wear and tear on joints, merely providing symptomatic relief from pain while failing to prevent 'joint failure' and regenerate damaged joint tissues 2, 5 . However, recently developed regenerative therapies employing mesenchymal stem cells (MSCs) or stromal vascular fraction (SVF) have shed light on clinical treatments for OA, providing substantial evidence in favor of cartilage regeneration and immunoregulation [6] [7] [8] [9] [10] . In 2011, autologous SVF, which comprises the heterogeneous cell populations released after the enzyme hydrolysis of adipose tissue, including adipose stromal cells, hematopoietic stem cells, endothelial cells, fibroblasts, lymphocytes, erythrocytes, monocyte/macrophages, and pericytes [11] [12] [13] [14] , was first applied in OA patients in combination with HA to induce cartilage regeneration; clinically, this treatment resulted in an alleviated visual analog score (VAS), improved range of motion, and magnetic resonance imaging (MRI) evidence of cartilage regeneration at 3-month follow up 6 . Since then, multiple clinical studies have demonstrated the efficacy of SVF for the treatment of OA. In 2013, a case series was reported in which autologous SVF with autologous platelet-rich plasma (PRP) was injected to treat 18 OA patients after arthroscopic debridement and lavage, and improved Western Ontario and McMaster Universities osteoarthritis index (WOMAC) scores, Lysholm knee scoring scales, VAS scores, and MRI evaluations were achieved 7 . Another study also demonstrated significant improvements in VAS scores, the knee injury and osteoarthritis outcome score (KOOS), and a second-look arthroscopic evaluation in 21 OA patients after treatment with autologous SVF with PRP compared with PRP alone in 23 OA patients 8 . Taken together, these data suggest SVF may represent a potentially effective therapeutic approach for the treatment of OA.
Adipose mesenchymal stem cells (ASCs) have also been widely investigated both preclinically and clinically for the treatment of OA 9, 15 because ASCs have advantages in terms of their cell source as well as lower immunogenicity and stronger immunoregulatory ability compared with bone marrow-derived MSCs (BM-MSCs) 16, 17 . Our group recently observed that xenogeneic human ASCs engrafted into rabbit articular cartilage after 4 to 10 weeks of intra-articular (IA) injections promoted articular cartilage regeneration in a rabbit OA model 18 . Furthermore, we investigated the in vivo biodistribution of labeled-xenogeneic human ASCs in an immunocompetent rat OA model and observed the proliferation of engrafted human cells within the injected joint for approximately 10 weeks, indicating a correlation between cell therapy efficacy and a physical presence 19 . However, to the best of our knowledge, there is no direct evidence comparing the efficacy of autologous SVF and autologous ASCs for the treatment of OA in a large animal model that is similar to humans 20 . Thus, it is important to understand whether the IA injection of autologous ASCs achieves better therapeutic efficacy than autologous SVF for preventing OA progression and to determine how long autologous ASCs must remain in the joint to observe efficacy (that is, the persistence of autologous stem cell therapy).
To address these important questions, we isolated and administered sheep adipose-derived autologous ASCs and autologous SVF in combination with HA into OA knees to determine whether autologous ASCs combined with HA are more effective in blocking OA progression compared with autologous SVF combined with HA in a standard large animal model. In addition, to evaluate the correlation between autologous ASC persistence and efficacy, ASCs were labeled with superparamagnetic iron oxide particles (SPIOs) and injected into OA knee joints in combination with HA for longitudinal detection by MRI.
Materials and Methods

Study Design and Animal Model
A total of 34 male small tail Han sheep (Jiagan Biotech, Shanghai, China), approximately 6 months old, skeletal immature, with a mean weight of 30+5 kg, were used in this study. Among them, 4 sheep were set aside for the in vivo tracking study, while the other 30 sheep were randomly allocated to the following five treatment groups: Saline group (treated with 5 ml of normal saline, n¼6); HA group (treated with 2.5 ml of saline þ 2.5 ml of HA, n¼6); ASC low-dose group (treated with 1Â10 7 ASCs/2.5 ml of saline þ 2.5 ml of HA, n¼6); ASC high-dose group (treated with 5Â10 7 ASCs/2.5 ml of saline þ 2.5 ml of HA, n¼6); and SVF group (treated with SVF containing 1Â10 7 mononuclear cells/2.5 ml of saline þ 2.5 ml of HA, n¼6). A medium molecular weight (600-1500 kDa) of 2.5 mg/ml HA (Jingfeng Pharmaceuticals, Shanghai, China) was used in the study. Grouping details and corresponding treatments are described in Table 1 . Anterior cruciate ligament transection (ACLT) and medial meniscectomy (MM) of the right knee were performed according to previously described methods 21 . The non-surgery healthy knee joints were used as 'non-injured' group. After surgery, all sheep were permitted to exercise freely during daily life to ensure the occurrence of OA. At 7 weeks after knee surgery, each sheep underwent a second surgery to isolate adipose tissues from the cervicothoracic region for the generation of autologous SVF or ASCs. At 12 weeks after ACLT and MM, fresh ASCs and SVF were harvested to treat OA sheep according to their grouping, respectively. At 15 weeks, cryopreserved ASCs and SVF were used as a second dose. At 27 weeks after ACLT and MM (3 months after the second injection), all sheep were euthanized, and the knee joints were evaluated by performing imaging and histological analyses. For the tracking study (n¼4), 5Â10
7 SPIO-labeled ASCs were injected into each sheep to track cell signals by performing MRI. The sheep were euthanized at week 14 or week 30 ( Fig. 1) . All animal protocols were approved by the Ethics Committee of Shanghai Jiao Tong University School of Medicine, and all subsequent experiments were performed in accordance with relevant guidelines and regulations 22 .
Isolation of SVF and ASCs
Adipose tissue (24.02+9.31 g) was collected from each sheep at 7 weeks after ACLT and MM surgery to harvest autologous SVF or ASCs as previously described 23, 24 . Briefly, adipose tissues were first washed three times in phosphate-buffered saline (PBS) to remove red blood cells and tissue debris; then, fat was digested with 0.2% collagenases IV (Sigma C5138) (Sigma-Aldrich, St. Louis, MO, USA) at 37 C for 1.5 h. SVF pellets were obtained by centrifugation at 425 g for 5 min, followed by resuspension. The average yield of SVF was 1.88Â10 6 25 . Briefly, for adipogenic and osteogenic differentiations, cells were seeded and grown in StemPro ® adipogenesis and osteogenesis differentiation medium (Gibco, Carlsbad, USA) for 3 weeks, respectively. For chondrogenic differentiation, micromass culture was used and cells were cultured in StemPro ® chondrogenesis differentiation medium (Gibco) for 4 weeks.
MRI Analysis for Therapeutic Efficacy
To evaluate the therapeutic efficacy of joint tissues, three sheep from each group were randomly selected for MRI using a 3.0 T MR System (MAGNETOM Skyra, Siemens, Germany) pre-operatively as well as 12 weeks and 27 weeks after surgery. All analyses were performed by three blinded experts (Drs XL, LL, and HY) using the magnetic resonance observation of cartilage repair tissue (MOCART) scoring system with sagittal T1-FSE (TR, 380 ms; TE, 25 
Macroscopic Evaluation and mCT Analysis
In each group, femoral condyles of three randomly selected sheep were macroscopically evaluated according to the International Cartilage Research Society (ICRS) scores for cartilage repair 27, 28 . ICRS is a 3-point scoring system, each part being assigned a score between 0 and 4, giving an index with a range of 0 to 12 points (normal, 12; nearly normal, 11-8; abnormal, 7-4; and severely abnormal, 3-0). For mCT analysis (Scanco mCT40, Switzerland), all tibia samples were incubated for 15 minutes in 50 ml 20% Cysto Conray II/80% PBS at 37 C, and evaluated in an animal bed, providing a voxel size of 45 mm, and scanned at 70 kVp, 114 mA, 200 ms integration time, and 15-30 minutes acquisition time. In order to accurately segment the tibia articular cartilage from the subchondral bone, contour lines for the Saline (n¼6) 5 ml 0.9% normal saline 5 ml 0.9% normal saline HA (n¼6) 2.5 ml 0.9% normal saline þ 2.5 ml HA 2.5 ml 0.9% normal saline þ 2.5 ml HA Low (n¼6) 1Â10 7 ASCs/2.5 ml saline) þ 2.5 ml HA
1Â10
7 ASCs/2.5 ml saline) þ 2.5 ml HA High (n¼6) 5Â10 7 ASCs/2.5 ml saline) þ 2.5 ml HA
5Â10
7 ASCs/2.5 ml saline) þ 2.5 ml HA SVF (n¼6) 1Â10 7 SVF/2.5 ml saline) þ 2.5 ml HA
1Â10
7 SVF/2.5 ml saline) þ 2.5 ml HA Tracing (n¼4) 5Â10 7 SPIO-ASCs/2.5 ml saline) þ 2.5 ml HA / ASC: adipose mesenchymal stem cell; HA: hyaluronic acid; SPIO: superparamagnetic iron oxide particle; SVF: stromal vascular fraction. articular cartilage and subchondral bone were manually drawn, and semi-automatic contouring was applied every 3-10 slices. The lower threshold was 30 HU (Hounsfield Unit), the upper threshold was 1000 HU (Gauss filter parameters: sigma¼1.2, support¼2) to segment cartilage from bone tissue according to the histogram analysis of the tissues. Direct distance transformation algorithms were used to quantify the average cartilage thickness from the bird's-eye view 29 . All macroscopic and mCT evaluations were performed by three blinded experts (Drs JH, HX, and DJ).
Histological and Immunohistochemical Analysis
Femoral condyle samples were collected and fixed in 4% paraformaldehyde for one week, followed by decalcification in ethylenediaminetetraacetic acid (EDTA)-buffered saline solution (pH 7.4, 0.25 mol/l) for 3 months at room temperature. Samples were then dehydrated via serial ethanol washing and embedded in paraffin for sectioning (6 mm for each section). To assess the general morphology of the articular cartilage samples, sections obtained from sheep in each group underwent histological staining, including H&E (hematoxylin & eosin) staining and safranin-O and fast green staining (Sigma-Aldrich). Cartilage thickness was quantitatively assessed by three blinded experts (Drs JH, HX, and DJ), according to previously described methods 30 . To identify hypertrophic chondrocytes in the cartilage, immunohistochemical staining using polyclonal rabbit anti-sheep collagen X antibodies (1:200) (GeneTex, Irvine, CA, USA) was performed.
Detection of Cytokines in Synovial Fluid
To determine whether levels of inflammatory cytokines and growth factors in knee joints changed after treatment, 1.5 ml of synovial fluid was collected from each knee joint at 27 weeks after surgery. Inflammatory cytokines, including interleukin (IL)-1b, IL-6, and IL-10, growth factors including transforming growth factor (TGF)-b1 and insulin-like growth factor (IGF)-1, and the chemokine stromal cell-derived factor (SDF)-1a were detected with commercial enzyme-linked immunosorbent assay (ELISA) kits (RayBiotech, Norcross GA, USA) according to the manufacturer's instructions.
Immunoblot Analysis
To detect type X collagen protein levels, protein was extracted from cartilage samples at 27 weeks after euthanasia. Collagen X expression was detected using a standard immunoblot technique. Polyclonal rabbit anti-sheep collagen X antibodies (1:300) (GeneTex) and polyclonal rabbit glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies (1:1000) (Cell Signaling Technology, Beverly, MA, USA) were applied. Detection was performed using an enhanced chemiluminescence detection kit (Thermo Fisher Scientific). The intensity of each band was normalized to GAPDH.
Autologous ASC Labeling and Longitudinal MRI Tracing
A total of 5Â10 7 autologous ASCs at passage 4 were isolated from four individual sheep and labeled with SPIO (Biopal, Worcester, USA) according to the manufacturer's instructions. The SPIO-labeled autologous ASCs were then delivered into the OA knee joint of each sheep 12 weeks after ACLT. SPIO signals were tracked non-invasively using a 3.0 T MR imaging system (MAGNETOM Skyra, Siemens, Germany) under T2* sequence conditions (TR, 445 ms; TE, 4.36 ms; FOV, 159 mm; matrix, 384Â384; flip angle, 60 ; slice thickness, 3 mm; spacing between slices, 3.6 mm) at 0 (12 weeks post-surgery), 6 (18 weeks post-surgery), 12 (24 weeks post-surgery), and 18 weeks (30 weeks postsurgery) after IA delivery of cells. Prussian blue staining was used to identify SPIO particles in articular cartilage sections. In order to exclude the possibility that SPIO positive cells were not the macrophages which swallowed labeled SPIO particles by phagocytosis, CD68 immunohistochemistry was also performed using mouse polyclonal anti-sheep CD68 antibody (Santa Cruz, 1:100).
Statistical Analysis
The data are expressed as the mean + SE. Differences among groups were tested for statistical significance by performing Kruskal-Wallis test followed by Dunn's post-test. P-values less than 0.05 were considered statistically significant.
Results
Autologous ASCsþHA Demonstrated Better Efficacy than SVFþHA for the Treatment of OA At 12 weeks after ACLT and MM, MRI showed an absence of the anterior cruciate ligament and medial meniscus, fuzziness of the articular cartilage contour, effusion of the articular cavity, and bone marrow edema, indicating OA was successfully induced ( Fig. 2A) . At 27 weeks after ACLT and MM (12 weeks after the second injection), the autologous ASCþHA and SVFþHA groups all exhibited a more glossy, continuous, and intact layer of articular cartilage than the HA alone and saline alone groups ( Fig. 2A) . In particular, effusion of the articular cavity and defects in the cartilage and subchondral bone were obvious in both the HA alone and saline alone groups, demonstrating the efficacy of autologous ASCþHA and SVFþHA therapy. MOCART scores, which were evaluated by three independent observers, demonstrated the significantly increased efficacy of the low-dose ASCþHA treatment compared with the SVFþHA, HA alone, and saline alone groups (Fig. 2B) .
Macroscopic evaluations of the articular surface of the femoral condyles in each group were performed by three independent observers, and ulcerations in the articular cartilage were evident in the saline alone and HA alone groups, although HA treatment showed better efficacy than that of the saline group, whereas cartilage ulceration was alleviated with the autologous ASCþHA and SVFþHA treatments (Fig. 3A) . Low-dose ASCþHA treatment (1Â10 7 cells) resulted in a smoother and more continuous cartilage surface compared with SVFþHA treatment (1Â10 7 cells): obvious ulcerations were observed in the trochlear groove area in three of six sheep in the SVFþHA group, while high-dose ASCþHA treatment (5Â10 7 cells) yielded an even more continuous and intact articular surface than did the lowdose ASCþHA and SVFþHA treatments (Fig. 3A) . Similarly, mCT evaluations of the tibia plateau revealed a continuous and intact cartilage layer with no obvious cartilage destruction in the autologous high-dose and low-dose ASCþHA treatment groups, whereas visible structural changes and cartilage damage were observed in the saline, HA, and SVFþHA groups although there were no significant differences in the average cartilage thickness of tibial plateau among ASCþHA, SVFþHA, and HA alone groups ( Fig. 3B and D) . The low-dose ASCþHA treatment group had significantly higher ICRS scores compared with the saline and HA groups; however, the SVFþHA and high-dose ASCþHA groups had no significance of ICRS scores compared with the saline and HA groups. (Fig. 3C) . Thus, IA injection of autologous ASCsþHA and SVFþHA efficiently blocked OA pathogenesis and achieved superior therapeutic efficacy compared with that observed in the HA and saline groups. However, ASCþHA had better efficacy than SVFþHA for the treatment of OA when considering the ICRS score of the femoral condyle.
Histological Analysis revealed Good Cartilage Quality following the Autologous ASCþHA and SVFþHA Treatments
Histological results for both H&E staining (Fig. 4A) and safranin-O/fast green staining (Fig. 4B ) of the medial epicondyle of the femur further revealed typical, homogenous articular cartilage structures with smooth, continuous surfaces and strong proteoglycan staining in the ASCþHA-and SVFþHA-treated groups, whereas rough and fractured surfaces with remarkably heterogeneous cartilage structures were observed in the saline and HA groups (Fig. 4A, 4B) . Furthermore, cartilage thickness of the femoral condyle in the high-dose ASCþHA-treated group was also significantly thicker than that observed in the HA and saline groups, although SVFþHA and low-dose ASCþHA treatments resulted in no significance of cartilage thickness compared with that of the HA and saline groups (Fig. 4C) . Based on these results, IA injection of autologous ASCsþHA and Fig. 1 . Schedule and design of the study. At 1 day before surgery, three sheep were randomly selected to perform baseline MRI. In total, 34 sheep were performed ACLTþMM in which 30 sheep were divided into saline, HA, low ASCþHA, high ASCþHA, and SVFþHA groups, and 7 weeks later another operation took place to isolate adipose tissue manufacturing SVF and ASCs. At 12 and 15 weeks after surgery, each group was treated by different interventions. 30 sheep were sacrificed at week 27 after surgery. The remaining four sheep were used in the tracking study with SPIO-labeled ASC injection at week 12 and sacrificed at week 14 and week 30, respectively. ACLT: anterior cruciate ligament transection; ASC: adipose mesenchymal stem cell; HA: hyaluronic acid; MM: medial meniscectomy; MRI: magnetic resonance imaging; SPIO: superparamagnetic iron oxide particle; SVF: stromal vascular fraction. , and 27 weeks post-operation in different treatments (noninjured, saline, HA, low ASCþHA, high ASCþHA, and SVFþHA). In the pre-op and non-injured groups, T2 sequence of 3.0 T MRI showed smooth cartilage layer and clear synovium lining; however, at 12 weeks post-surgery and in the saline and HA groups, the T2 sequence of the MRI exhibited damaged cartilage and hydropic synovium. ASCþHA and SVFþHA treatments improved cartilage injury, bone marrow lesions of subchondral bone, synovial hydropic swelling. (B) MOCART scores in low-dose ASCþHA treatment were significantly higher than those in the saline and HA groups. The P-values were obtained using a Kruskal-Wallis test and Dunn's post-test (*P<0.05). Data were collected from three repetitions (n¼3). ASC: adipose mesenchymal stem cell; HA: hyaluronic acid; MOCART: magnetic resonance observation of cartilage repair tissue; MRI: magnetic resonance imaging; OA: osteoarthritis; SVF: stromal vascular fraction. staining revealed that autologous ASCþHA and SVFþHA-treated groups presented typical articular cartilage structure and ECM staining with smooth, continuous surface similar to the non-injured group, while the saline and HA groups showed an obvious eroded structure with a rough, cracked surface at 27 weeks post-surgery (12 weeks post second injection). (C) Cartilage thickness of femoral condyles in the high ASCþHA group was significantly thicker than the saline and HA groups. Cartilage thicknesses were calculated from the surface layer (zone I) across transitional stratum (zone II), and radiate stratum (zone III) to calcified cartilage (zone IV). Scale bars indicate 500 mm. The P-values were obtained using Kruskal-Wallis test and Dunn's post-test (**P<0.01). Data were collected from three repetitions (n¼3). ASC: adipose mesenchymal stem cell; ECM: extracellular matrix; H&E: hematoxylin & eosin; HA: hyaluronic acid; SVF: stromal vascular fraction.
SVFþHA efficiently blocks OA progression, and high-dose ASCþHA treatment achieved better therapeutic efficacy compared with SVFþHA when considering the cartilage matrix and femoral cartilage thickness.
We also examined the expression of type X collagen, a hypertrophic-chondrocyte-specific marker, in the treatment groups. The immunohistochemistry results indicated that hypertrophic chondrocytes expressing collagen X were aligned in the deep articular cartilage in the non-injured group (Fig. 5A) . Few collagen-X-positive chondrocytes were observed in the saline and HA treatment groups. In contrast, high-dose ASCþHA treatment rescued hypertrophic chondrocytes expressing collagen X in the deep area of articular cartilage (Fig. 5A ). There were greater numbers of collagen-X-positive hypertrophic chondrocytes in the low-dose ASCþHA group than in the SVFþHA group. Furthermore, Western blotting analysis indicated the highand low-dose ASCþHA groups expressed more collagen X than did the SVFþHA group (Fig. 5B) .
In conclusion, these data suggest autologous ASCþHA treatments especially high-dose ASCþHA treatment may promote the regeneration of articular cartilage by increasing cartilage thickness in addition to blocking OA progression.
ASCþHA Treatment exerted Anti-Inflammatory and Trophic Effects
Next, we compared the anti-inflammatory and trophic effects of ASCþHA and SVFþHA treatment. Levels of inflammatory cytokines, including IL-1b, IL-6, and IL-10, growth factors including TGF-b1 and IGF-1, and the chemokine SDF-1 were examined in synovial fluid that was collected 12 weeks after the second injection. High-dose ASCsþHA significantly inhibited IL-1b and IL-6 expression, while the low-dose ASCsþHA and SVFþHA had no significance compared with the saline group. No treatments significantly reduced IL-10 levels, although the high-and low-dose ASCþHA and SVFþHA treatments trended toward reduced IL-10 levels (Fig. 6C) . Levels of the chondrogenic agonists TGF-b1 and IGF-1 were also detected, and no treatments significantly increased TGF-b1 and IGF-1 levels, although the high-and low-dose ASCþHA and SVFþHA treatments trended toward enhanced TGF-b1 and IGF-1 levels in synovial fluid ( Fig. 6D  and E) . Additionally, SVFþHA treatment significantly increased SDF-1 levels in the synovial fluid, whereas the lowand high-dose ASCþHA treatments did not affect SDF-1 expression (Fig. 6F) . 
SPIO Signals Were Present 18 Weeks After Injection and Resided in the Menisci and Marrow Cavities of the Femoral Condyles
To further understand the clearance of autologous ASCs and because high-dose ASCþHA appeared to be more efficacious than low-dose ASCþHA, we explored the persistence of high-dose ASCs labeled with SPIO in the knee joint. After 12 weeks of ACLT and MM, 5Â10 7 (high-dose) SPIO-labeled autologous ASCs combined with HA were injected into the OA joint. SPIO signals were detected in the synovium, suprapatellar bursa, and popliteal fossa by MRI until 18 weeks after the injection (30 weeks after ACLT and MM) (Fig. 7A) . Prussian blue staining was also used to evaluate the localization of SPIO-labeled cells, and SPIO signals were primarily observed at the edge of the lateral meniscus but not in the articular cartilage at 2 weeks post-injection (14 weeks after ACLT and MM), (Fig. 7B) . Moreover, safranin-O/fast green staining confirmed the presence of SPIO signals in the collagen-I-positive meniscus (Fig. 7B) . At 18 weeks post-injection (30 weeks after ACLT and MM), CD68-negative SPIO signals were detected in the marrow cavities of the medial femoral condyles (Fig. 7B) , indicating the SPIO particles were not phagocytosed by macrophages.
Discussion
Previous studies from our laboratory revealed the engraftment of xenogeneic human ASCs into rabbit and rat articular cartilage and the inhibition of inflammatory factor levels in synovial fluid 18, 19 ; synovial inflammation is a trigger for OA symptoms, and soluble inflammatory factors increase cartilage damage 31, 32 . Recently, a proof-of-concept clinical trial treated OA with 1-10Â10 7 autologous ASCþHA and demonstrated improved WOMAC scores at 6 months after injection in the 10Â10 7 dose group, and arthroscopy and histological assessments showed substantial, thick, hyaline- like cartilage regeneration, indicating the feasibility of stem cell therapy for OA 9 . SVF was first injected with HA and PRP into the knee joints of OA patients in 2011, resulting in decreased VAS pain scores, ameliorated FRI joint function, and improved regeneration of the articular cartilage and subchondral bone 6 . Moreover, in another case series, SVF was injected after arthroscopic debridement and lavage into 37 OA knees with lesion sizes of 5.4+2.9 cm 2 , and follow up at 26.5 months (24-34 months) revealed significant improvement of both the mean IKDC (International Knee Documentation Committee) and Tegner activity scale scores. A high body mass index (BMI) (!27.5 kg/m 2 ) and a large lesion size (!5.4 cm 2 ) were significant predictors of poor clinical and arthroscopic outcomes 8 . Most recently, micro-fracture in the presence and absence of SVF and PRP injection were also investigated to treat grade 2 or 3 Lawrence scale OA patients clinically. A mixture of SVF ( 5Â10 7 ) and activated PRP was injected after arthroscopic micro-fracture into 15 patients (58.60+6.48 years old), while another 15 OA patients (58.20+5.71 years old) received only microfracture as a control. During follow up, WOMAC scores in both groups significantly decreased compared with the baseline at 6 and 12 months after treatment; however, at 18 months after treatment, WOMAC scores in the microfracture group deteriorated and were not significantly different compared with the baseline, while WOMAC scores in the micro-fracture þ SVF group improved continuously 33 . However, one of the main disadvantages of using autologous SVF in OA patients is the lack of availability of randomized controlled studies; only case reports or cohort studies have been conducted. Despite the beneficial results published by these case reports and cohort studies, further investigation is necessary to accept SVF as a standard cell therapy treatment for OA. Additionally, both ASCs and SVF are heterogeneous cell populations, and both have shown efficacy for the treatment of OA, but it is not clear which is more efficacious. In this study, two injections of both autologous ASCþHA and SVFþHA improved MOCART scores of OA animals to the same extent (Fig. 2) . Macroscopic and histological evaluations of the same treatment dose (1Â10 7 ) indicated autologous ASCþHA resulted in better cartilage uniformity than that observed in the SVFþHA group, although both autologous ASCþHA and SVFþHA treatments demonstrated efficacy (Figs. 3 and 4) .
SVF contains colony-forming unit fibroblasts (CFU-Fs) at a frequency of 1-10% and expresses the stromal cellassociated markers CD13, CD29, CD44, CD63, CD73, CD90, CD 105, and CD146, although these stromal markers are expressed at very low levels 12, 34, 35 . A CFU-F assay was performed to evaluate the frequency of mesenchymal progenitors in SVF. Positive CFU-F and stromal cell-associated characteristics may explain why SVF showed efficacy in blocking OA in the current study; although it is not a homogeneous cell population, SVF contains mesenchymal stromal cells, and its final mesenchymal stromal population composition has varied considerably in different studies due to differing fluorescent-activated cell sorting techniques, cellular extraction steps, and adipose tissues extracted from different regions of the body 34 . Furthermore, the presence of mesenchymal stromal cell populations may also explain why SVF trended toward increased TGF-b1 levels in synovial fluid. In contrast, ASCs are less heterogeneous than SVF cells because they expand from an adherent cell population and contain CFU-F at a frequency of 1:3+2 at passage 4, thus demonstrating greater numbers of mesenchymal progenitors and superior multipotency 12 . This might explain why the efficacy of ASCþHA was superior to that of SVFþHA in the current study. The current study not only undertook macroscopic and histological analyses of articular cartilage but also investigated synovial inflammation. Our results were consistent with previous investigations in which SVF demonstrated less potency to decrease IL-1b and IL-6 levels ( Fig. 6A and B) , which in turn promoted cartilage catabolic responses 36 . SDF-1 plays an important role in OA progression: SDF-1 secreted by synoviocytes combines with the C-X-C chemokine receptor type 4 (CXCR4) receptor on the chondrocyte membrane and activates the Erk and P38 mitogen-activated protein kinase signaling pathway to induce matrix metalloproteinase (MMP) expression and degradation of the extracellular matrix (ECM) 37, 38 . In our study, SVFþHA increased SDF-1 secretion (Fig. 6F) , whereas ASCþHA treatments did not, suggesting the superior efficacy of ASCþHA for the treatment of OA.
Recently, the efficacies of BM-MSCs and SVF for the treatment of OA were investigated, showing no significant effects 39 . However, the primary concern regarding this study is the differing dosages of SVF and BM-MSCs. Horses (n¼8) in the SVF group received a total of 1.63Â10 7 nucleated cells, which is equivalent to 0.2Â10 7 SVF cells per OA horse, whereas horses (n¼8) in the BM-MSC group received a total of 1.05Â10 7 BM-MSCs, which is equivalent to 0.13Â10 7 BM-MSCs per OA horse. Another concern is the application of only one small dose (0.13-0.2Â10 7 BM-MSCs or SVF cells): efficacy may not have been observed because one dose might not be sufficient to treat a skeletally mature horse with OA. Additionally, the followup period may have been too short to observe efficacy. In our study, the same dose (1Â10 7 cells) of ASC and SVF was applied to treat OA sheep. Moreover, two large doses were administered due to animal body weight consideration. OA was induced in 30 kg sheep, and a second dose (1Â10 7 cells) was given 3 weeks after the first to ensure efficacy. Finally, we followed up for 12 weeks (15 weeks after the first injection) rather than 8 weeks to evaluate efficacy. In summary, larger doses, repeated injections, lower animal body weights, and a longer follow-up period may explain why efficacy was observed in the current study.
From a pharmacological perspective, it is very important to understand the pharmacokinetic/pharmacodynamic relationship for a cell therapy 'drug' Since SVF is usually used when fresh, and the labeling protocol often requires overnight culture, co-culturing SVF with a labeling reagent overnight would damage cells in the hematopoietic subgroup of SVF, resulting in labeling difficulties. Therefore, in the current study, we labeled only autologous ASCs to detect persistence. Moreover, the SVF yield from adipose tissue made it difficult to deliver 5Â10 7 cells per dose. The efficacy of high-dose ASCþHA appeared superior to that of low-dose ASCþHA. Thus, high-dose ASCs were labeled in combination with HA to evaluate their lifespan after IA injection. We labeled the ASCs with SPIO, a 35-nm non-transfectionbased fluorescent iron oxide nanoparticle, traced their localization after joint injection in a large animal model of OA and observed the presence of SPIO signals for 18 weeks by MRI (30 weeks after ACLT and MM surgery), which included the efficacy assessment time point at week 12. Interestingly, histological examination detected signals only at the surface of the lateral menisci and bone marrow cavities of the femoral condyles (Fig. 7B) . However, we can only exclude the phagocytosis by macrophages but the SPIO positive cells might not be the injected ASCs. Further investigation at multiple timepoints should be conducted to survey various tissues and clarify whether autologous ASC engraftment to cartilage is an efficacy requirement.
There are certain limitations to this study. For example, simultaneously acquiring a large group of nearly 40 adult sheep was difficult. Thus, we used adolescent sheep to explore the efficacy of cell therapy. However, OA primarily occurred in adults, although a previous study demonstrated the synovial homogeneity of immature and adult sheep with respect to the consistently low expression of the inflammatory factors TNF-a, IL-1b, and IL-6, which are essential for the initiation and development of OA 40 . Furthermore, the current study prepared autologous sheep ASCs and SVF to demonstrate the effective blockade of cartilage destruction and promotion of cartilage regeneration in a sheep OA model following repeated injections of bona fide autologous ASCs and SVF. Whereas SVF is often used fresh, cryopreserved SVF and ASCs were used in the current study for the second injection at week 15 because it was very difficult to perform a third surgery to isolate adipose tissue from each sheep. Further studies are necessary to address this problem. Additionally, this issue reveals the limitations of SVF for clinical applications, while ASCs may be passaged to expand their population. Another limitation is that we mainly focus on cartilage changes in the current study but OA is an organ disease with cartilage degradation, subchondral bone sclerosis, ligament retrogression, synovium hyperplasia, and joint capsule hypertrophy 2 . Although MRI exhibited ASCþHA-improved hydropic synovium and bone marrow lesions of subchondral bone (Fig. 2) , the detailed pathological assays of subchondral bone, ligament, synovium, and joint capsule were not exhibited. Further investigations should be performed to address all these limitations.
Conclusions
The current study demonstrated significantly improved MOCART and ICRS scores following treatment with lowdose ASCsþHA compared with SVFþHA treatment. Although no differences were exhibited in terms of cartilage thickness of the tibial plateau (Fig. 3D) , high-dose ASCþHA treatment resulted in a significant increase in cartilage thickness of the femoral epicondyle, while low-dose ASCþHA and SVFþHA treatments showed no differences in improving cartilage thickness of the femoral epicondyle. Based on the synovial fluid data, only high-dose ASCþHA treatment inhibited IL-1b and IL-6 expressions. Furthermore, only SVFþHA treatment enhanced SDF-1 expression in synovial fluid. In conclusion, IA injection of autologous ASCþHA may result in better efficacy than autologous SVFþHA in blocking OA progression and promoting cartilage regeneration, and autologous ASCs (5Â10 7 cells) may survive for at least 18 weeks after IA injection.
